In order to investigate whether epigenetic signatures could define molecular subgroups of MBCs, we examined methylation profiles of MBC cases, characterized for BRCA1/2 mutation status, by performing promoter methylation analysis of genes representative of cellular pathways known to be involved in breast cancer. This evidence concerns the gene BRCA1 and breast carcinoma.